Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine

A technology for serum thymus factor and chemotherapeutic drugs, which is applied in the field of application of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physics and chemotherapeutic drugs

Inactive Publication Date: 2008-07-30
中国生化制药工业协会
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there are no patents and research reports on the applica

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine
  • Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine
  • Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0050] Example 1

[0051] This example relates to the EAC ascites tumor group results

[0052] Subcutaneous injection was administered, animals were inoculated on day 0, and culture conditions were checked on day 1. If there was no contamination, the animals were weighed and randomized into groups to start administration. The tumor model mice were randomly divided into 5 groups, namely the high-dose group, the middle-dose group, the low-dose group, the positive control group and the blank group, with the high-dose 0.25 mg·kg respectively. -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; the positive drug group, 5-fluorouracil, once every other day, three times in total. The results are shown in Table 1:

[0053] Table 1 Results of FTS used for anti-EAC ascites tumor drugs (x±s, n=10)

[0054] group

[0055] △△ P △△△ P<0.001 compared with blank group; life extension rate w...

Example Embodiment

[0057] Embodiment 2

[0058] This example involves the results of the H22 solid tumor group

[0059] Subcutaneous injection was administered, animals were inoculated on day 0, and culture conditions were checked on day 1. If there was no contamination, the animals were weighed and randomized into groups to start administration. The tumor model mice were randomly divided into 5 groups, namely the high-dose group, the middle-dose group, the low-dose group, the positive control group and the blank group, with the high-dose 0.25 mg·kg respectively. -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except for the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide was administered once. The results are shown in Table 2.

[0060] Table 2. Results of FTS for anti-H22 solid tumor drugs (x±s, n=10)

[0061] group

[0062] △△ P △△△ P<0.001 compared with blank group; tumor inhibition rate was compared with blank group.

[0063]...

Example Embodiment

[0064] Embodiment 3

[0065] This example relates to the Walker-256 tumor group results

[0066] Subcutaneous injection was administered, animals were inoculated on day 0, and culture conditions were checked on day 1. If there was no contamination, the animals were weighed and randomized into groups to start administration. The tumor model rats were randomly divided into 5 groups, namely the high-dose group, the middle-dose group, the low-dose group, the positive control group and the blank group, with the high-dose 2.2 mg·kg respectively. -1 , medium dose 1.1mg·kg -1 , low dose 0.55mg·kg -1 , except for the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide was administered once. The results are shown in Table 3.

[0067] The solid tumors in the administration group were dissected out and weighed the next day after the last administration, and the tumor inhibition rate was calculated. The tumor inhibition rates in the administration gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses applications of serum thymus factor (FTS) in preparation of anti-tumor medicines, protective medicine or immunity intensified medicines for physical treatment and chemical treatment of tumor. Experimental results reveal that all groups of tumor-bearing mice and W256 rat fed with medicines are significantly different from groups fed with physiological saline and the tumor inhibition rates of all the groups fed with the medicines are more than 30 percent, thus confirming the tumor inhibition effect of the FTS. The FTS can also enhance the immunity activity and strengthen the immunity function of living organisms in a plurality of aspects; the FTS has no toxicity and less side effects; the effective wide dose scope and wide safety range. The FTS has obvious protective function to immunity indexes of living organisms, which is discovered in the study of the protective medicines for the physical and chemical treatment medicines of tumor. Therefore, the FTS can provide a new target and development for the clinical treatment of tumor.

Description

technical field [0001] The invention relates to a new application of biochemical substances in pharmaceutical engineering, more specifically the application of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs or immune-enhancing drugs. Background technique [0002] Cancer is one of the main causes of human death. According to the statistics of the World Health Organization, there are about 5 million patients who die of cancer every year in the world. In recent years, due to the deterioration of our living environment, the incidence of cancer has increased, and there is a trend of younger patients. It can be seen that the prevention and treatment of cancer is very urgent. Drug therapy is one of the main treatments for cancer. Over the past century, remarkable achievements have been made in the drug treatment of cancer, and dozens of anti-tumor drugs have been developed, which effectively prolong the l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/08A61P35/00
Inventor 徐康森乐嘉静廖晓泉王悦张长平李湛君
Owner 中国生化制药工业协会
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap